Formulation
| Each vial contains: | |
|---|---|
| Triptorelin (as embonate) | 3.75 mg, 11.25 mg, or 22.5 mg |
Triptorelin
Pamorelin®
Prescription Drug
Indication
- Palliative treatment of locally advanced, non-metastatic hormone dependent prostate cancer.
- Adjuvant treatment of metastatic hormone dependent prostate cancer.
- Adjuvant treatment to radio therapy in patients with high risk localized or locally advanced prostate cancer.
- Treatment of endometriosis
Dosage and Administration
For more information on safety, precaution and other information about this product, please see the Product Insert.
Please consult your physician and other healthcare providers before taking any prescription medicines found on this site. The contents found on this page are for information purposes only. It should not be construed as a substitute for professional medical advise and should not be relied upon in that regard. You undertake to carefully read all product packaging and labels prior to use.
Caution: Food, Drugs, Devices and Cosmetics Act prohibits dispensing without prescription.
ARTICLE
What is Prostate Cancer and Are You at Risk
Six out of ten cases of prostate cancer are found in men aged 65 and over since the risk levels significantly rise you grow older.
ARTICLE
Essential Medical Tests for Women in their 40s
Life begins at 40! Live a healthier lifestyle by scheduling routine checkups that are tailor-made for your age.
.webp)
ARTICLE
Severe Pain 101: How This Can Affect Health and Productivity
Get to the bottom of severe or intense pain today. Learn why these happen and how to address them effectively before they ruin your productivity.